Introduction
Mycobacterium abscessus belongs to a group of rapidly growing mycobacteria, which are Runyon group IV organisms that usually form colonies on solid media within 7 days.
1 M. abscessus is the most resistant mycobacterium of the known pathogenic rapidly growing mycobacteria, and causes a wide spectrum of clinical diseases, including localized soft tissue infections, pulmonary disease and disseminated infections. 2 Soft tissue infection by M. abscessus is typically caused by contamination of a wound with infected material, non-sterile surgical procedures, injections, implantations of foreign bodies or in connection with tympanic tubes. M. abscessus causes over 80% of rapidly growing mycobacteria chronic respiratory disease. 3 Such pulmonary diseases are especially common in patients with cystic fibrosis. Various types of systemic immunosuppression may also predispose individuals to disseminated M. abscessus infections. Clarithromycin and azithromycin are the only effective oral antimycobacterial agents for M. abscessus and should, preferably, be supplemented with other drugs since long-term monotherapy may cause resistance. 1 Amikacin is a major parenteral drug used to treat M. abscessus that should also be given in combination with another drug. 2 Because of the variable susceptibility of M. abscessus to cefoxitin, imipenem and ciprofloxacin, antibiotic susceptibility testing of all clinically significant isolates is recommended. 4 To our knowledge, M. abscessus infection is a rare disease and so case numbers are limited. Two studies have reviewed the clinical outcomes of 126 patients and 29 patients respectively, 3, 5 and the only other related publications are case reports. Because it is not a common disease, the relationship between the clinical outcome of M. abscessus infection and its antimicrobial susceptibility has never been evaluated in Taiwan. Hence, we assess the clinical manifestations of M. abscessus infections, antimicrobial susceptibility and responses to antimicrobial therapy.
Methods

M. abscessus isolates
Forty M. abscessus isolates were obtained from the sputum (n = 35), blood (n = 4) and cornea (n = 1) of 40 patients at Taichung Veterans General Hospital from January 2006 to December 2008.
Antimicrobial susceptibility testing
Susceptibility testing was performed using the broth microdilution method according to the recommendations of the National Committee for Clinical Laboratory Standards. 6 The isolates were grown on blood agar and incubated at 30°C in room air. The minimal inhibitory concentrations (MIC) were read on the 3 rd and 4 th days.
The inocula were prepared from actively growing bacteria in 10 mL of cation-adjusted Mueller-Hinton broth. 
Clinical assessment and definitions
The diagnostic criteria for pulmonary M. abscessus infection were those outlined in the recommendations of the clarithromycin, amikacin and other active antimicrobial agents may lead to clinical improvement; however, the rate of treatment failure is still high. 
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For the purpose of analysis, we divided each lung into two zones (upper and lower lobes), and each zone was assessed separately. The radiographic patterns were classified as reticulonodular opacities, consolidation and cavitary lesions.
Outcome measurement
Outcome measurement was performed at the end of the 12 th month after the start of treatment. 
Microbiological outcomes
Microbiological responses were based on the results of the appropriate cultures. Eradication was defined as absence of M. abscessus on culture. Persistence was defined as presence of M. abscessus in a patient with clinical failure. Indeterminate outcome was defined as assessment not possible for any reason.
Results
The results of antimicrobial susceptibility testing are shown in Table 1 . The susceptibility rates of the 40 M. abscessus isolates to the nine antimicrobial agents were as follows: amikacin (95.0%), cefoxitin (32.5%), ciprofloxacin (10.0%), clarithromycin (92.5%), doxycycline (7.5%), imipenem (12.5%), moxifloxacin (22.5%), sulfamethoxazole (7.5%) and tigecycline (100%). Twenty-two patients were diagnosed with M. abscessus infection. Eighteen M. abscessus isolates from 18 patients were considered as colonization. The clinical manifestations are shown in Tables 2 and 3 . Symptoms included cough (86.3%), hemoptysis (31.8%), fever (18.1%), chest pain (9.1%), dyspnea (4.5%), body weight loss (4.5%) and skin rash (4.5%). Some of the 22 patients had associated disorders, including previous episodes of tuberculosis (7/22 , 31.8%), chronic obstructive pulmonary disease (3/22, 13.6%), diabetes mellitus (5/22, 22.7%), and malignancy (3/22, 13.6%). Of the three patients with M. abscessus bacteremia that received antimicrobial therapy, one died due to recurrent bacteremia 6 months later, and the other two patients died from unrelated causes.
The most common radiographic finding was reticulonodular opacities (11 patients, 50.0%), predominantly in the right upper lung. Cavitary lesions (4 patients, 18.1%) were seen in upper the lobes and were predominant in the right upper lobe. Consolidation (7 patients, 31.8%) was distributed in right upper and left lower lobes. One or both upper lobes were involved in 76% of the patients. Multi-lobar (involving 3 or more lobes) involvement was seen in 19% of patients, and bilateral lobe involvement was seen in 52%. Lymph node enlargement was not seen in any of the radiographs. Table 4 lists the clinical and microbiological outcomes. The clinical outcomes at the end of the 12 th month after the start of treatment were as follows: cure (5 patients, 22.7%); improvement (3 patients, 13.6%); failure (6 patients, 27.2%); and indeterminate outcome (8 patients, 36.3%). The microbiological outcomes at the end of the 12 th month after the start of treatment were as follows: eradication (7 patients, 31.8%); persistence (7 patients, 31.8%); and indeterminate outcome (8 patients, 36.3%).
Discussion
The main clinical symptoms of M. abscessus infection in this study included cough, hemoptysis and fever. Cough was also the most common symptom, along with other frequent symptoms such as low-grade fever, hemo ptysis, sputum production and weight loss in previous studies. 1, 8 In this study, we found that patients had higher rates (40%) of structural lung disease, including previous episodes of pulmonary tuberculosis and chronic obstructive pulmonary disease. Disorders associated with M. abscessus infection, such as bronchiectasis and prior mycobacterial infection, were also observed in a previous study. 4 Disseminated non-tuberculous Mycobacterial disease is rare in non-human immunodeficiency virus-infected hosts and is associated with various immunosuppressive conditions (e.g. renal or cardiac transplantation, chronic corticosteroid use, and hematologic malignancy). 1, 7 In this study, one patient had a history of acute lympho blastic leukemia and five patients had diabetes mellitus. Characteristics of the radiographic findings included reticulonodular opacities, consolidation and cavitary lesions. These findings were comparable to those described in previous studies. 3, 9 The high resolution CT scan of one patient with M. abscessus pulmonary disease showed diffuse bronchiectasis. In contrast, the most common CT findings in a previous study were branching nodular opacities and cylindrical bronchiectasis. 9 In patients with pre-existing pulmonary tuberculosis, the new infiltrate of M. abscessus infection generally occurred in the same area as the previous disease. 8 In this study, the most active antimicrobial agents against the 40 M. abscessus isolates were tigecycline (100%), amikacin (95.0%) and clarithromycin (92.5%), while the others were less active. Surveillance data collected by the Multicenter Antimicrobial Resistance in Taiwan  (SMART program) 4 This discrepancy between eradication rates and antimicrobial susceptibility may be due to structural lung disease or immunosuppressive conditions. For M. abscessus pulmonary disease, radical surgery may be curative when it is possible to perform, but pulmonary operations on this patient group are associated with significant risks. 12 The combination of tigecycline for 2 weeks plus clarithromycin for 8 months resulted in both cure and eradication in one patient. The new drug tigecycline is promising. It has low MIC values (≤ 0.03-1 μg/mL) for M. abscessus, but needs further clinical evaluation before a definite role in therapy can be established. 13, 14 M. abscessus is partially susceptible (23%) to linezolid in vitro, with an MIC ≤ 8 μg/mL, but its long-term use is limited due to its hematological and neurological side effects, as well as its high price. 15, 16 In summary, M. abscessus is naturally susceptible to clarithromycin and amikacin, variably susceptible to cefoxitin and imipenem, and resistant to most antimicrobial drugs. Susceptibility testing is recommended to guide antimicrobial therapy for M. abscessus infections. Combination therapy with clarithromycin, amikacin and other active antimicrobial agents may result in clinical improvement; however, the rate of treatment failure is still high. The effect of combination treatment remains to be determined.
